[Significance, pathomechanism and prevention of risk factors in first-dose-hypotension in the therapeutic use of ACE inhibitors].
A number of megatrials gave convincing evidence concerning the beneficial effect of ACE inhibitors in acute myocardial infarction. But according to the trials mentioned above, the phenomenon of first dose hypotension is unfavourable by all means, especially in the subgroup of patients with borderline hypotension. The arising question is whether the first dose hypotension is an inevitable concomitant of the ACE inhibitor therapy. The authors review in details the results of experiments and clinical experiences concerning the pathomechanism of first dose hypotension, as well as the potential explanation of the lack of this phenomenon as regards perindopril therapy. The authors render account of their experiences gained with reference to administrating perindopril to 78 patients with acute myocardial infarction.
Moser
G
G
Szent Rókus Kórház, IV. Belgyógyászat, Budapest.
Együd
F
F
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D001920:Bradykinin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007022:Hypotension / Q000139:chemically induced* / Q000517:prevention & control; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D009203:Myocardial Infarction / Q000188:drug therapy*; D020913:Perindopril; D012307:Risk Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D007211:Indoles; D001920:Bradykinin; D020913:Perindopril
Elsö dózis hypotonia jelentösége, patomechanizmusa, veszélyei és elkerülésének módja ACE-gátló terápia során.